Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.43 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1552482 | 1.00 | KMT2A (0.60) | KMT2AL3MBTL1JAK1KDM1AMAOB | |
| SCHEMBL19051699 | 1.00 | KMT2A (0.60) | KMT2AL3MBTL1JAK1KDM1AMAOB | |
| SCHEMBL30404117 | 1.00 | KMT2A (0.60) | KMT2AL3MBTL1JAK1KDM1AMAOB | |
| SCHEMBL13520171 | 1.00 | KMT2A (0.60) | KMT2AL3MBTL1JAK1KDM1AMAOB | |
| SCHEMBL2378151 | 1.00 | KMT2A (0.60) | KMT2AL3MBTL1JAK1KDM1AMAOB | |
| SCHEMBL9929564 | 1.00 | KMT2A (0.60) | KMT2AL3MBTL1JAK1KDM1AMAOB | |
| SCHEMBL17304781 | 0.93 | KMT2A (0.65) | KMT2AL3MBTL1JAK1KDM1AMAOB | |
| SCHEMBL1815532 | 0.90 | KMT2A (0.65) | KMT2AL3MBTL1JAK1KDM1AMAOB | |
| SCHEMBL25263326 | 0.88 | KMT2A (0.60) | KMT2AL3MBTL1JAK1KDM1AMAOB | |
| SCHEMBL21166304 | 0.88 | KMT2A (0.60) | KMT2AL3MBTL1JAK1KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568946-A1 | MACROCYCLIC BCL6 DEGRADERS | Dana-Farber Cancer Institute, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119585240-A | Macrocyclic BCL6 degrading agents | 丹娜-法伯癌症研究院 | 2025-03-07 | — | — | CN | disclosed |
| WO-2024035688-A1 | MACROCYCLIC BCL6 DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| EP-3484871-B1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3668863-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2020056089-A1 | PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2020-03-19 | — | — | WO | disclosed |
| WO-2019036377-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| EP-3057948-B1 | SELECTIVELY SUBSTITUTED QUINOLINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2018-03-14 | — | — | EP | disclosed |
| EP-2475667-A1 | INHIBITORS OF JAK | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| EP-1999106-B1 | A HYDRIDE REDUCTION PROCESS FOR PREPARING QUINOLONE INTERMEDIATES | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2012-06-27 | — | — | EP | disclosed |
| US-7528264-B2 | Hydride reduction process for preparing quinolone intermediates | THE PROCTER & GAMBLE COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| US-20090111991-A1 | Coupling Process For Preparing Quinolone Intermediates | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2009-04-30 | — | — | US | disclosed |
| EP-2001862-A2 | MALATE SALTS, AND POLYMORPHS OF (3S,5S)-7-Ý3-AMINO-5-METHYL-PIPERIDINYL¨-1-CYCLOPROPYL-1,4-DIHYDRO-8-METHOXY-4-OXO-3-QUINOLINECARBOXYLIC ACID | The Procter and Gamble Company (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1999125-A2 | A COUPLING PROCESS FOR PREPARING QUINOLONE INTERMEDIATES | The Procter and Gamble Company (US) | 2008-12-10 | — | — | EP | disclosed |
| US-7456279-B2 | Coupling process for preparing quinolone intermediates | THE PROCTER & GAMBLE COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070232650-A1 | Malate salts, and polymorphs of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid | THE PROCTER & GAMBLE COMPANY | 2007-10-04 | — | — | US | disclosed |
| WO-2007110834-A2 | MALATE SALTS, AND POLYMORPHS OF (3S,5S)-7-[3-AMINO-5-METHYL-PIPERIDINYL]-1-CYCLOPROPYL-1,4-DIHYDRO-8-METHOXY-4-OXO-3-QUINOLINECARBOXYLIC ACID | THE PROCTER & GAMBLE COMPANY (US) | 2007-10-04 | — | — | WO | disclosed |
| US-20070232804-A1 | Coupling process for preparing quinolone intermediates | THE PROCTER & GAMBLE COMPANY (US) | 2007-10-04 | — | — | US | disclosed |
| WO-2007110835-A2 | A COUPLING PROCESS FOR PREPARING QUINOLONE INTERMEDIATES | THE PROCTER & GAMBLE COMPANY (US) | 2007-10-04 | — | — | WO | disclosed |
| US-20070232806-A1 | Hydride reduction process for preparing quinolone intermediates | THE PROCTER & GAMBLE COMPANY (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232804-A1 | Coupling process for preparing quinolone intermediates | CYP3A4, CYP4B1, CYP4X1 | KMT2A 2928/4885L3MBTL1 4612/4885JAK1 3205/4885 |
| US-20090111991-A1 | Coupling Process For Preparing Quinolone Intermediates | CYP3A4, CYP4B1, CYP4X1 | KMT2A 2928/4885L3MBTL1 4612/4885JAK1 3205/4885 |
| US-20070232650-A1 | Malate salts, and polymorphs of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid | SLC25A11, MDH2, MDH1 | KMT2A 2561/4885L3MBTL1 4292/4885JAK1 1510/4885 |
| US-20070232806-A1 | Hydride reduction process for preparing quinolone intermediates | NQO1, NQO2, POR | KMT2A 1279/4885L3MBTL1 4297/4885JAK1 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.